Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0882420080740060593
Korean Journal of Medicine
2008 Volume.74 No. 6 p.593 ~ p.595
Remission induction using arsenic trioxide in acute promyelocytic leukemia
Min Chang-Ki

Abstract
In acute promyelocytic leukemia (APL), all-trans retinoic acid (ATRA) triggers cell differentiation, while arsenic trioxide (ATO) generates partial differentiation and apoptosis. Standard initial treatment for patients with APL consists of chemotherapy, usually an anthracycline, and ATRA. It now appears that it is important to administer consolidation chemotherapy and to include ATRA in both the induction and maintenance phases of treatment. ATO, which is rarely associated with cardiac toxicity, has been shown to be the best reported salvage therapy for patients with APL who relapse following an initial remission. Moreover, ATO treatment can yield a high quality clinical/molecular remission and disease-free survival in relapsed as well as newly diagnosed APL patients. ATO may be effective as first-line treatment for APL, even though the results of ATO combination therapy with chemotherapy/ATRA requires further study.
KEYWORD
Acute promyelocytic leukemia, Remission induction, All-trans retinoic acid, Arsenic trioxide
FullTexts / Linksout information
 
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø